Who Owns KPTI?

Karyopharm Therapeutics Inc. — Institutional Ownership & 13F Holdings

$8.57

-0.09 (-1.04%)

Market Cap

$73.9M

Shares Outstanding

8,537,286

Institutional Holders

47

Total Inst. Value

$13.9M

% of Float Held

66.6%

QoQ Holder Change

Institutional data as of Q1 2025

Top 10 Institutional Holders(Q1 2025)

#FundValueShares
1VANGUARD GROUP INC$1.9M510,294
2ADAGE CAPITAL PARTNERS GP, L.L.C.$1.6M421,322
3Exome Asset Management LLC$1.5M2,000,000
4Eversept Partners, LP$962K257,154
5BlackRock, Inc.$908K242,742
6CITADEL ADVISORS LLC$774K206,909
7JPMORGAN CHASE & CO$638K170,790
8Catalio Capital Management, LP$582K155,622
9T. Rowe Price Investment Management, Inc.$523K139,646
10Avidity Partners Management LP$503K134,566

Famous Fund Managers

Related Stocks

Frequently Asked Questions

How many institutional investors hold KPTI?

As of Q1 2025, 47 institutional investors report holding KPTI (Karyopharm Therapeutics Inc.) in their 13F filings.

What percentage of Karyopharm Therapeutics Inc. is owned by institutions?

Institutional investors hold approximately 66.6% of Karyopharm Therapeutics Inc.'s float as reported in SEC 13F filings.

Which hedge fund owns the most KPTI?

The largest institutional holder of KPTI is VANGUARD GROUP INC with $1.9M in shares.

Are institutions buying or selling KPTI?

This quarter, 47 institutions opened new positions in KPTI and 1 closed their positions.

What is 13F institutional ownership?

SEC Form 13F is a quarterly report filed by institutional investment managers with over $100M in qualifying assets. It discloses their US equity holdings, providing transparency into what the largest investors are buying and selling.

How often is institutional ownership data updated?

13F filings are due 45 days after each calendar quarter end (May 15, Aug 14, Nov 14, Feb 14). Data is updated on HedgeTrace as new filings are processed.